Standardization of Two Dpcr Platforms for Detection of BCR/ABL1 - Minimal Residual Disease (MRD) in Ph+ Chronic Myeloid Leukemia (CML)

Background: despite the international efforts on standardization, qPCR has some intrinsic limitations of accuracy and sensitivity that make it suboptimal to assess lower levels of BCR-ABL1. In recent years, digital PCR (dPCR) has emerged to provide a more sensitive and accurate detection of minimal residual disease (MRD), that accounts for the increasing interest for its use in the clinic. The Qx100/Qx200 Droplet Digital PCR System (ddPCR, Biorad) and Quant Studio 3D dPCR System (Thermofisher) are the most widespread platforms commonly used. However nowadays internationally recognized operational protocols are not available.